Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062546 | 0.79 | MET (0.64) | MET | |
| Hydrochloric Acid SCHEMBL3066851 | 0.78 | MET (0.63) | MET | |
| SCHEMBL3062469 | 0.68 | MET (0.45) | METBRD4GRIN1GRIN2BALDH1A1 | |
| SCHEMBL3096140 | 0.65 | MET (0.72) | MET | |
| SCHEMBL12241124 | 0.63 | MET (0.61) | MET | |
| SCHEMBL12241146 | 0.63 | MET (0.61) | MET | |
| SCHEMBL3090364 | 0.61 | MET (0.70) | MET | |
| SCHEMBL3090717 | 0.60 | MET (1.00) | MET | |
| SCHEMBL12241162 | 0.60 | MET (0.58) | MET | |
| SCHEMBL12241201 | 0.60 | MET (0.57) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885BRD4 791/4885GRIN1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.